Published in J Clin Oncol on March 27, 2006
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet (2009) 4.52
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A (2007) 4.15
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature (2010) 3.70
Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell (2009) 3.11
The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res (2009) 3.03
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol (2011) 2.82
Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med (2009) 2.73
The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A (2009) 2.72
The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer (2011) 2.60
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol (2011) 2.53
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell (2012) 2.45
A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell (2012) 2.15
An animal model of MYC-driven medulloblastoma. Cancer Cell (2012) 2.12
The clinical implications of medulloblastoma subgroups. Nat Rev Neurol (2012) 2.12
Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell (2016) 2.12
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol (2010) 2.04
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest (2011) 1.87
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res (2011) 1.80
OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res (2009) 1.77
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol (2015) 1.72
Medulloblastoma stem cells. J Clin Oncol (2008) 1.71
BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res (2013) 1.64
Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev (2012) 1.64
Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol (2010) 1.60
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Challenging issues in pediatric oncology. Nat Rev Clin Oncol (2011) 1.56
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med (2007) 1.48
Development and cancer of the cerebellum. Trends Neurosci (2011) 1.47
N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev (2009) 1.45
Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting. Protein Cell (2010) 1.45
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Cerebellum development and medulloblastoma. Curr Top Dev Biol (2011) 1.40
Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro Oncol (2008) 1.39
Recurrent genomic alterations characterize medulloblastoma arising from DNA double-strand break repair deficiency. Proc Natl Acad Sci U S A (2009) 1.37
Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol (2011) 1.36
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res (2011) 1.33
Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One (2009) 1.33
MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One (2010) 1.31
Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol (2012) 1.30
DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol (2013) 1.27
Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets Ther (2012) 1.27
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res (2013) 1.20
Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med (2013) 1.14
Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. Pediatr Blood Cancer (2012) 1.14
Chemotherapy for malignant brain tumors of childhood. J Child Neurol (2008) 1.14
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol (2013) 1.12
Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro Oncol (2008) 1.12
WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum. Development (2012) 1.12
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol (2016) 1.11
Role of MYC in Medulloblastoma. Cold Spring Harb Perspect Med (2013) 1.10
Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J Neuropathol Exp Neurol (2011) 1.10
Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro Oncol (2011) 1.10
Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol (2010) 1.09
Treatment of pediatric brain tumors. J Cell Physiol (2008) 1.09
CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. Cancer Res (2011) 1.09
Childhood brain tumors: epidemiology, current management and future directions. Nat Rev Neurol (2011) 1.09
An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET). Br J Cancer (2009) 1.08
Atoh1 inhibits neuronal differentiation and collaborates with Gli1 to generate medulloblastoma-initiating cells. Cancer Res (2010) 1.08
Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro Oncol (2008) 1.07
Molecular subgroups of medulloblastoma. Expert Rev Neurother (2012) 1.05
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget (2011) 1.05
Defining a role for Sonic hedgehog pathway activation in desmoplastic medulloblastoma by identifying GLI1 target genes. Int J Cancer (2009) 1.04
Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. Neoplasia (2010) 1.03
Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro Oncol (2011) 1.03
Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget (2014) 1.02
Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. J Exp Clin Cancer Res (2014) 1.01
Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol (2014) 1.01
Molecular diagnostics in embryonal brain tumors. Brain Pathol (2011) 1.00
High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol (2011) 1.00
Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes Dev (2014) 1.00
PCAF ubiquitin ligase activity inhibits Hedgehog/Gli1 signaling in p53-dependent response to genotoxic stress. Cell Death Differ (2013) 1.00
Genetic drivers of metastatic dissemination in sonic hedgehog medulloblastoma. Acta Neuropathol Commun (2014) 1.00
Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathol (2015) 1.00
The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells. PLoS One (2013) 0.99
Severe alterations of cerebellar cortical development after constitutive activation of Wnt signaling in granule neuron precursors. Mol Cell Biol (2011) 0.98
Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A (2015) 0.98
Aggressive infantile embryonal tumors. J Child Neurol (2008) 0.96
EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nat Neurosci (2015) 0.95
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol (2016) 0.95
Sleeping Beauty mutagenesis in a mouse medulloblastoma model defines networks that discriminate between human molecular subgroups. Proc Natl Acad Sci U S A (2013) 0.95
Identification of suitable endogenous control genes for microRNA expression profiling of childhood medulloblastoma and human neural stem cells. BMC Res Notes (2012) 0.94
The molecular classification of medulloblastoma: driving the next generation clinical trials. Curr Opin Pediatr (2012) 0.94
Integrated analysis of miRNA and mRNA expression in childhood medulloblastoma compared with neural stem cells. PLoS One (2011) 0.93
Sequential activation of Snail1 and N-Myc modulates sonic hedgehog-induced transformation of neural cells. Cancer Res (2011) 0.92
Subgroup-specific alternative splicing in medulloblastoma. Acta Neuropathol (2012) 0.92
Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma. Proc Natl Acad Sci U S A (2009) 0.92
International network of cancer genome projects. Nature (2010) 20.35
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity (2011) 6.00
Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell (2004) 5.95
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature (2008) 5.59
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23
Radial glia cells are candidate stem cells of ependymoma. Cancer Cell (2005) 5.21
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 4.94
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol (2006) 4.72
Inactivation of the p53 pathway in retinoblastoma. Nature (2006) 4.57
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet (2009) 4.52
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature (2010) 3.70
Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol (2004) 3.56
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol (2011) 3.56
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol (2011) 3.33
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol (2009) 3.32
BGEM: an in situ hybridization database of gene expression in the embryonic and adult mouse nervous system. PLoS Biol (2006) 3.24
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell (2011) 3.11
The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res (2009) 3.03
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Res (2006) 2.95
Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol (2009) 2.95
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol (2011) 2.82
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82
Cancer in adolescents and young adults: treatment and outcome in Victoria. Med J Aust (2004) 2.75
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med (2009) 2.73
The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A (2009) 2.72
A molecular fingerprint for medulloblastoma. Cancer Res (2003) 2.66
The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer (2011) 2.60
YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev (2009) 2.58
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol (2011) 2.53
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell (2012) 2.45
Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist (2004) 2.45
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell (2008) 2.42
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle (2006) 2.37
Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol (2013) 2.34
Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol (2012) 2.34
Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol (2005) 2.34
Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg (2006) 2.31
A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. Proc Natl Acad Sci U S A (2005) 2.19
Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol (2005) 2.19